Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01294670 · ClinicalTrials.gov registry record · Phase 1

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

A Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
11
Study locations

NCT01294670: Completed Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01294670 is a Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01294670, a Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets a protein(s) that control the way cancer cells grow and divide. Vorinostat is approved by the FDA in adults with certain cancers but not approved yet in children. There are two parts to this study. In the first part of this study, the phase I portion, a safe dose of the combination, vorinostat and etoposide. The goal of second part of this study, the phase II portion, is to see how effective the combination of vorinostat and etoposide is in treating cancer.

Primary Outcome

of the novel combination vorinostat and etoposide in pediatric patients with refractory solid tumors including tumors of the central nervous system. The Toxicity will be evaluated according to NCI CTCAE Version 4.0.

Conditions Studied

Solid Tumors Relapsed/Refractory Sarcomas

Interventions

  • DRUG Vorinostat and Etoposide

Study Locations (11)

Florida

  • Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando - Orlando
  • All Children's Hospital - St. Petersburg

Arizona

  • Phoenix Children'S Hospital - Phoenix

Colorado

  • Children's Hospital Colorado - Aurora

Maryland

  • John Hopkins Medical Center - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Children's Mercy Hospital & Clinics - Kansas City

New York

  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Pennsylvania State University College of Medicine - Hershey

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-02-09
Est. Completion 2020-12-08
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT01294670 record still lists

NCT01294670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Vorinostat and Etoposide is the first listed.

NCT01294670 lists 11 locations in 10 states (Florida, Arizona, Colorado).

Frequently Asked Questions

What is clinical trial NCT01294670 about?

NCT01294670 is a clinical study titled "Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors". The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets ...

What is the current status of trial NCT01294670?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-02-09. Estimated completion is 2020-12-08.

What conditions does trial NCT01294670 study?

This clinical trial studies the following conditions: Solid Tumors, Relapsed/Refractory Sarcomas.

What interventions are being tested in trial NCT01294670?

The interventions under investigation include: Vorinostat and Etoposide (DRUG).

Who is sponsoring clinical trial NCT01294670?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01294670 being conducted?

This trial has 11 study locations across Arizona, Colorado, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01294670's enrollment target sits among peer trials

27 110th of 125 higher than 15 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01294670, the US trial registry maintained by the National Library of Medicine. NCT01294670 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.